Clinical Medicine Insights-Oncology

Papers
(The H4-Index of Clinical Medicine Insights-Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The RNA m6A-Binding Protein YTHDC1 Is Downregulated and Associated With M2 Macrophage Infiltration in Muscle-Invasive Bladder Cancer54
Treatment Continuity and Bone Marrow Suppression in Whole-Brain and Whole-Spinal Cord Radiotherapy for Medulloblastoma Patients46
Predictive Value of Plasma Epstein-Barr Virus DNA Concentration for Recurrence and Metastasis in Advanced-Stage Nasopharyngeal Carcinoma: A Longitudinal, Descriptive Investigation38
Patterns of Different Cervical Cytokine Expression in High-Risk Human Papillomavirus–Infected Patients With Cervical Cancer and Its Precancerous Lesions34
Modifiable Risk Factors Including Self-Perceived Stress for Breast Cancer in Hong Kong: A Case-Control Study of 10 757 Subject33
Augmented Reality Navigation-Assisted Laparoscopic Hepatectomy: A Retrospective Comparison of Anatomical and Non-anatomical Resection22
Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: a Review of Evidence19
Is the Urinary and Gut Microbiome Associated With Bladder Cancer?16
Assessment of Cardiotoxicity Incidence in Patients Receiving HER-2-Targeted Therapies for Breast Cancer in Saudi Arabia15
Initial Low-Dose Dacomitinib for First-Line Treatment of Patients With EGFR Exon 21-Mutated Non-Small-Cell Lung Cancer15
Utility of Circulating Tumor DNA Assay in Identifying Mutations and Guiding Matched Targeted Therapy in Lung Cancers15
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study15
Advances and Future Expectations in Oncolytic Virus Therapy for Glioblastoma: A Systematic Review of Clinical Trials14
Integrating Salivary Biomarkers CST4 and miR-223 With Health-Related Factors for Gastric Cancer Detection and Risk Assessment14
0.085455894470215